Updates are available Correction dated 2023-01-10
Click to view Correction: https://doi.org/10.1038/s41586-022-05632-x
-
Authors
Vellano, Christopher P.
White, Michael G. http://orcid.org/0000-0001-5022-5505
Andrews, Miles C. http://orcid.org/0000-0003-1231-8641
Chelvanambi, Manoj http://orcid.org/0000-0003-2130-3118
Witt, Russell G.
Daniele, Joseph R.
Titus, Mark
McQuade, Jennifer L. http://orcid.org/0000-0002-2393-2172
Conforti, Fabio
Burton, Elizabeth M.
Lastrapes, Matthew J.
Ologun, Gabriel
Cogdill, Alexandria P. http://orcid.org/0000-0001-8917-9462
Morad, Golnaz http://orcid.org/0000-0002-9460-618X
Prieto, Peter
Lazar, Alexander J. http://orcid.org/0000-0002-6395-4499
Chu, Yanshuo
Han, Guangchun http://orcid.org/0000-0001-9277-2507
Khan, M. A. Wadud http://orcid.org/0000-0003-0596-862X
Helmink, Beth
Davies, Michael A. http://orcid.org/0000-0002-0977-0912
Amaria, Rodabe N. http://orcid.org/0000-0001-6876-278X
Kovacs, Jeffrey J.
Woodman, Scott E.
Patel, Sapna http://orcid.org/0000-0003-1339-1517
Hwu, Patrick
Peoples, Michael
Lee, Jeffrey E. http://orcid.org/0000-0001-6010-5590
Cooper, Zachary A. http://orcid.org/0000-0003-1059-0940
Zhu, Haifeng
Gao, Guang
Banerjee, Hiya
Lau, Mike http://orcid.org/0000-0001-5076-3944
Gershenwald, Jeffrey E. http://orcid.org/0000-0003-4519-5369
Lucci, Anthony
Keung, Emily Z.
Ross, Merrick I.
Pala, Laura
Pagan, Eleonora
Segura, Rossana Lazcano
Liu, Qian
Borthwick, Mikayla S. http://orcid.org/0000-0003-2620-2076
Lau, Eric
Yates, Melinda S. http://orcid.org/0000-0001-9450-5517
Westin, Shannon N. http://orcid.org/0000-0002-1922-0156
Wani, Khalida
Tetzlaff, Michael T.
Haydu, Lauren E. http://orcid.org/0000-0002-6360-0199
Mahendra, Mikhila
Ma, XiaoYan
Logothetis, Christopher http://orcid.org/0000-0002-6365-1711
Kulstad, Zachary
Johnson, Sarah http://orcid.org/0000-0001-8936-0958
Hudgens, Courtney W. http://orcid.org/0000-0001-8312-7485
Feng, Ningping
Federico, Lorenzo
Long, Georgina V. http://orcid.org/0000-0001-8894-3545
Futreal, P. Andrew http://orcid.org/0000-0001-8663-2671
Arur, Swathi http://orcid.org/0000-0002-6941-2711
Tawbi, Hussein A. http://orcid.org/0000-0003-1942-851X
Moran, Amy E. http://orcid.org/0000-0003-1952-7737
Wang, Linghua http://orcid.org/0000-0001-9380-0266
Heffernan, Timothy P. http://orcid.org/0000-0002-3166-8922
Marszalek, Joseph R.
Wargo, Jennifer A. http://orcid.org/0000-0003-3438-7576
- License Information
-
More Information
Article History
Received: 12 August 2020
Accepted: 5 May 2022
First Online: 15 June 2022
Change Date: 10 January 2023
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41586-022-05632-x
Competing interests
: J.A.W. is listed as an inventor on a US patent application (PCT/US17/53.717); reports compensation for speaker’s bureau and honoraria from Imedex, Dava Oncology, Omniprex, Illumina, Gilead, PeerView, MedImmune and Bristol-Myers Squibb (BMS); serves as a consultant/advisory board member for Roche/Genentech, Novartis, AstraZeneca, GlaxoSmithKline (GSK), BMS, Merck, Biothera Pharmaceuticals and Micronoma; and holds stock options from Micronoma. J.L.M. serves as a consultant for Merck and is on the advisory board for BMS. Z.A.C. is a current employee of and owns stock in AstraZeneca. M.C.A. reports advisory board participation and honoraria from MSD Australia outside the current work; received research funds to their institution from MSD Australia and BMS Australia outside the current work; and is a named co-inventor on patent applications relating to methods and compositions for treating cancer (WO2020106983A1) unrelated to the current work, and methods for improving sex-dimorphic responses to targeted therapy in melanoma (US20200164034A1) related to the current work. R.N.A. receives research support and advisory boards for Novartis, BMS, Iovance and research support from Genentech. C.L. serves as a consultant/advisory board for Merck, Sharp & Dohme, Exelixis, Bayer and Amgen; reports honoraria from Merck, Sharp & Dohme, Bayer and Amgen; and clinical grants from Janssen, ORIC Pharmaceuticals, Novartis and Aragon Pharmaceuticals. M.A.D. is an advisory board member/consultant for BMS, Novartis, Array, Roche/Genentech, GSK, Sanofi-Aventis and ABM Therapeutics; principal investigator of a research grant to their institution from Astrazeneca, Roche/Genentech, GSK, Myriad, Oncothyreon, Sanofi-Aventis and ABM Therapeutics. P.A.F. serves on the scientific advisory board for Scorpion Therapeutics. A.E.M. has a sponsored research agreement with MedImmune/AstraZeneca. S.N.W. serves as a consultant for Agenus, AstraZeneca, Caris, Clovis Oncology, Eisai, EQRX, GSK/Tesaro, ImmunoGen, Lilly, Merck, Pfizer, Mersana, Roche/Genentech and Zentalis; she receives research support to her institution from AstraZeneca, Bayer, Bio-Path, Clovis Oncology, Cotinga Pharmaceuticals, GSK/Tesaro, Mereo, Novartis, OncXerna, Roche/Genentech and Zentalis. A.J.L. has served on advisory boards and/or consulted for AbbVie, AstraZeneca, Bayer, BMS, Deciphera Pharmaceuticals, Foghorn Therapeutics, GSK, Invitae, Illumina, Iterion Therapeutics, Merck, Novartis, Nucleai, Paige.AI, Pfizer, Roche/Genentech and ThermoFisher. G.V.L. is a consultant advisor for Agenus, Amgen, Array Biopharma, Boehringer Ingelheim International, Bristol Myers Squibb, Evaxion Biotech A/S, Hexal (Sandoz Company), Highlight Therapeutics S.L., Merck Sharpe & Dohme (Australia) Pty Limited, Novartis Pharma, OncoSec Medical Australia, Pierre Fabre, Provectus, Qbiotics Group Limited, Regeneron Pharmaceuticals. The other authors declare no competing interests.
